Abstract
Introduction:
Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE.
Methods:
Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed.
Results:
Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation.
Conclusions:
Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage*
-
Adrenal Cortex Hormones / adverse effects
-
Adult
-
Aged
-
Antibodies, Antiphospholipid / blood
-
Antibodies, Antiphospholipid / drug effects
-
Antibodies, Antiphospholipid / genetics
-
Antiphospholipid Syndrome* / blood
-
Antiphospholipid Syndrome* / drug therapy
-
Antiphospholipid Syndrome* / genetics
-
Enzyme-Linked Immunosorbent Assay
-
Factor V / analysis
-
Female
-
Humans
-
Immunoglobulin G / blood
-
Immunoglobulin M / blood
-
Leprosy, Multibacillary / drug therapy
-
Leprosy, Multibacillary / genetics
-
Leprosy, Multibacillary / immunology*
-
Male
-
Middle Aged
-
Mutation
-
Polymorphism, Genetic
-
Prothrombin / analysis
-
Thalidomide / administration & dosage*
-
Thalidomide / adverse effects
-
Venous Thromboembolism / drug therapy
-
beta 2-Glycoprotein I / blood
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Antiphospholipid
-
Immunoglobulin G
-
Immunoglobulin M
-
beta 2-Glycoprotein I
-
factor V Leiden
-
Thalidomide
-
Factor V
-
Prothrombin